All In Biotech

NDA 220200 · Avyxa Holdings

Avopef

Etoposide · Intravenous · Topoisomerase Inhibitor

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Feb 13, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,914

435 Phase 3, 235 recruiting

FAERS reports

73,447

71,494 serious, 17,829 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE MYELOSUPPRESSION AVOPEF can cause severe myelosuppression resulting in infection or bleeding [see Warnings and Precautions (5.1) ] . Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm 3 or platelets less than 50,000 cells/mm 3 [see Warnings and Precautions (5.1) ] . Monitor complete blood cell counts, prior to the administration of AVOPEF and before each subsequent cycle, and at appropriate intervals during and after therapy [see Warnings and Precautions (5.1) ] . WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning . AVOPEF can cause severe myelosuppression resulting in infection or bleeding. ( 5.1 ) Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm 3 or platelets less than 50,000 cells/mm 3 . ( 5.1 ) Monitor complete blood cell counts, prior...

What it is approved for

From the label in effect Oct 7, 2026.

AVOPEF is a topoisomerase inhibitor indicated, in combination with other chemotherapy and/or immunotherapy, for the treatment of adult patients with: Refractory testicular cancer ( 1.1 ) Small cell lung cancer ( 1.2 ) 1.1 Refractory Testicular Cancer AVOPEF, in combination with chemotherapy, is indicated for the treatment of refractory testicular cancer in adult patients. 1.2 Small Cell Lung Cancer AVOPEF, in combination with chemotherapy and immunotherapy, is indicated for the first-line treatment of small cell lung cancer (SCLC) in adult patients.

Mechanism: Etoposide causes the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals, leading to cell cycle arrest, primarily at the G2 stage of the cell cycle, and cell death.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 13, 2026 Original approval · Type 3 - New Dosage Form LetterLabel
2 products under this application
  • AVOPEF · ETOPOSIDE 100MG/5ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • AVOPEF · ETOPOSIDE 500MG/25ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Etoposide" as an intervention, any sponsor and status, largest first.

All 1,914 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use8,393
  • febrile neutropenia7,746
  • neutropenia5,069
  • drug ineffective4,759
  • disease progression4,532
  • thrombocytopenia4,140
  • pyrexia3,405
  • anaemia3,353
  • sepsis2,998
  • product use in unapproved indication2,973
  • death2,838
  • pancytopenia2,784

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004792
2005881
2006745
2007988
20081,084
20091,045
20101,167
20111,773
20121,995
20131,567
20141,702
20152,269
20162,601
20173,664
20184,656
20194,902
20205,842
20215,788
20226,631
20236,994
20246,507
20255,644
20264,206

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,076 on PubMed

Sponsor: Avyxa Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.